A randomized, double-blind, multicenter, placebo-controlled phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia

Table 1 Patient characteristics

	Placebo N= 248	Pregabalin N= 250
Sex, n (%)
Male	31 (12.5)	24 (9.6)
Female	217 (87.5)	226 (90.4)
Hormonal status, n (%)
Premenopausal	133 (61.3)	140 (61.9)
Postmenopausal	84 (38.7)	86 (38.1)
Age (years)
<18, n (%)	0	0
18 to 44, n (%)	104 (41.9)	101 (40.4)
45 to 64, n (%)	123 (49.6)	125 (50.0)
≥65, n (%)	21 (8.5)	24 (9.6)
Mean ± SD	46.7 ± 12.6	47.9 ± 12.0
Range	19, 78	19, 80
Weight, kg
Mean ± SD	56.2 ± 9.0	55.5 ± 11.0
Range	38.9, 90.9	37.2, 104.8
Height, cm
Mean ± SD	158.5 ± 6.8	158.3 ± 6.4
Range	131.9, 179.6	143.8, 176.0
Duration since FM onset, months
Mean	62.0	69.6
Range	0.3, 508.8	0.3, 505.1

ISSN: 1478-6362